Cargando…

The N‐terminal p.(Ser38Cys) TIMP3 mutation underlying Sorsby fundus dystrophy is a founder mutation disrupting an intramolecular disulfide bond

Sorsby fundus dystrophy (SFD) is a macular degeneration caused by mutations in TIMP3, the majority of which introduce a novel cysteine. However, the exact molecular mechanisms underlying SFD remain unknown. We aimed to provide novel insights into the functional consequences of a distinct N‐terminal...

Descripción completa

Detalles Bibliográficos
Autores principales:	Naessens, Sarah, De Zaeytijd, Julie, Syx, Delfien, Vandenbroucke, Roosmarijn E., Smeets, Frédéric, Van Cauwenbergh, Caroline, Leroy, Bart P., Peelman, Frank, Coppieters, Frauke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6594137/ https://www.ncbi.nlm.nih.gov/pubmed/30668888 http://dx.doi.org/10.1002/humu.23713

Ejemplares similares

Clinical and biochemical effects of the E139K missense mutation in the TIMP3 gene, associated with Sorsby fundus dystrophy
por: Saihan, Z., et al.
Publicado: (2009)

Sorsby fundus dystrophy (SFD): A narrative review
por: Tsokolas, Georgios
Publicado: (2022)

Sorsby Fundus Dystrophy Mutation in Tissue Inhibitor of Metalloproteinase 3 (TIMP3) promotes Choroidal Neovascularization via a Fibroblast Growth Factor-dependent Mechanism
por: Qi, Jian Hua, et al.
Publicado: (2019)

Role of FGF and Hyaluronan in Choroidal Neovascularization in Sorsby Fundus Dystrophy
por: Wolk, Alyson, et al.
Publicado: (2020)

OCT angiography in the management of choroidal neovascular membrane secondary to Sorsby fundus dystrophy
por: Mohla, Aditi, et al.
Publicado: (2016)

Potential CRISPR Base Editing Therapeutic Options in a Sorsby Fundus Dystrophy Patient
por: Elsayed, Maram E. A. Abdalla, et al.
Publicado: (2022)

Can Novel Treatment of Age-Related Macular Degeneration Be Developed by Better Understanding of Sorsby’s Fundus Dystrophy
por: Gourier, Hanae C. Y., et al.
Publicado: (2015)

The retinal pigment epithelium in Sorsby Fundus Dystrophy shows increased sensitivity to oxidative stress-induced degeneration
por: Wolk, Alyson, et al.
Publicado: (2020)

Deglycosylation Increases the Aggregation and Angiogenic Properties of Mutant Tissue Inhibitor of Metalloproteinase 3 Protein: Implications for Sorsby Fundus Dystrophy
por: Qi, Jian Hua, et al.
Publicado: (2022)

Visual Outcome after Intravitreal Anti-VEGF Therapy for Macular Neovascularisation Secondary to Sorsby’s Fundus Dystrophy: A Systematic Review
por: Baston, Arthur, et al.
Publicado: (2021)

H Syndrome Presenting with Sinus of Valsalva Aneurysm and Possible Founder Mutation (p.Arg134cys) in Indian Patients
por: Amalnath, Deepak, et al.
Publicado: (2023)

Mutations in Splicing Factor Genes Are a Major Cause of Autosomal Dominant Retinitis Pigmentosa in Belgian Families
por: Van Cauwenbergh, Caroline, et al.
Publicado: (2017)

Founder BRCA1 mutations in Nepalese population
por: Mehta, Anurag, et al.
Publicado: (2022)

Recurrent and founder mutations in the Netherlands: the cardiac phenotype of DES founder mutations p.S13F and p.N342D
por: van Spaendonck-Zwarts, K. Y., et al.
Publicado: (2012)

Elongated axial length and myopia-related fundus changes associated with the Arg130Cys mutation in the LIM2 gene in four Chinese families with congenital cataracts
por: Wang, Xun, et al.
Publicado: (2021)

How old is this mutation? - a study of three Ashkenazi Jewish founder mutations
por: Greenwood, Celia MT, et al.
Publicado: (2010)

Haplotype Analysis of GJB2 Mutations: Founder Effect or Mutational Hot Spot?
por: Shinagawa, Jun, et al.
Publicado: (2020)

Identification of a founder BRCA2 mutation in Sardinia
por: Pisano, M, et al.
Publicado: (2000)

Evidence of a founder BRCA1 mutation in Scotland
por: Liede, A, et al.
Publicado: (2000)

Recurrent and Founder Mutations in the Netherlands: the Long-QT Syndrome
por: Hofman, N., et al.
Publicado: (2010)

BRCA1 founder mutations and ovarian cancer in Belarus
por: Savanevich, A, et al.
Publicado: (2015)

Isolated sulfite oxidase deficiency: a founder mutation
por: Mhanni, Aizeddin A., et al.
Publicado: (2020)

Mutational effects of Cys113 on structural dynamics of Pin1
por: Ikura, Teikichi, et al.
Publicado: (2019)

The clinical and mutational spectrum of B3GAT3 linkeropathy: two case reports and literature review
por: Colman, Marlies, et al.
Publicado: (2019)

Characterization of a mutation commonly associated with persistent stuttering: evidence for a founder mutation
por: Fedyna, Alison, et al.
Publicado: (2010)

Primary Founder Mutations in the PRKDC Gene Increase Tumor Mutation Load in Colorectal Cancer
por: Pálinkás, Hajnalka Laura, et al.
Publicado: (2022)

PKD2 founder mutation is the most common mutation of polycystic kidney disease in Taiwan
por: Yu, Chih-Chuan, et al.
Publicado: (2022)

BRCA1 founder mutations compared to ovarian cancer in Belarus
por: Savanevich, Alena, et al.
Publicado: (2014)

A Founder Mutation of the BRCA1-Gene in Western Sweden
por: Einbeigi, Zakaria, et al.
Publicado: (1999)

The Slavic NBN Founder Mutation: A Role for Reproductive Fitness?
por: Seemanova, Eva, et al.
Publicado: (2016)

Founder mutation in KCNJ10 in Pakistani patients with EAST syndrome
por: Abdelhadi, Ola, et al.
Publicado: (2016)

GNE Myopathy: Two Clusters with History and Several Founder Mutations
por: Argov, Zohar, et al.
Publicado: (2015)

Introduction of an ancient founder glycoprotein VI mutation into the Chilean population
por: Dalby, Amanda, et al.
Publicado: (2022)

Antisense Oligonucleotide-Based Downregulation of the G56R Pathogenic Variant Causing NR2E3-Associated Autosomal Dominant Retinitis Pigmentosa
por: Naessens, Sarah, et al.
Publicado: (2019)

Recurrent and founder mutations in the Netherlands: cardiac Troponin I (TNNI3) gene mutations as a cause of severe forms of hypertrophic and restrictive cardiomyopathy
por: van den Wijngaard, A., et al.
Publicado: (2011)

Fundus albipunctatus: novel mutations and phenotypic description of Israeli patients
por: Pras, Eran, et al.
Publicado: (2012)

Founder mutations in the Netherlands: familial idiopathic ventricular fibrillation and DPP6
por: Postema, P. G., et al.
Publicado: (2011)

Prevalence and impact of founder mutations in hereditary breast cancer in Latin America
por: Ashton-Prolla, Patricia, et al.
Publicado: (2014)

Characterization of an Italian Founder Mutation in the RING-Finger Domain of BRCA1
por: Caleca, Laura, et al.
Publicado: (2014)

Founder mutations in Tunisia: implications for diagnosis in North Africa and Middle East
por: Romdhane, Lilia, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_csa26j72oifal4ltld7s6m6j7c